Aarti Pharmalabs Reports Decline in Key Financial Metrics Amid Operational Challenges in June 2025

Aug 13 2025 09:23 AM IST
share
Share Via
Aarti Pharmalabs has announced its financial results for the quarter ending June 2025, highlighting operational challenges. Key metrics, including net sales, profit before tax, and profit after tax, have all declined compared to previous averages. The company also reported its lowest earnings per share in five quarters and a rising debt-equity ratio.
Aarti Pharmalabs has recently reported its financial results for the quarter ending June 2025, revealing notable challenges within its operations. The company has experienced a significant decline in key financial metrics, leading to an adjustment in its evaluation.

Net sales for the quarter stood at Rs 386.19 crore, reflecting a substantial reduction compared to the average of the previous four quarters, which was Rs 528.77 crore. This trend indicates a concerning trajectory for the company's sales performance. Similarly, profit before tax less other income (PBT) was recorded at Rs 63.85 crore, also showing a decline against the previous four-quarter average of Rs 87.65 crore. Profit after tax (PAT) followed suit, landing at Rs 49.50 crore, down from an average of Rs 68.10 crore in the prior quarters.

Additionally, the company reported its lowest earnings per share (EPS) in the last five quarters at Rs 5.46, signaling a decline in profitability. The debt-equity ratio has reached its highest point in the last five half-yearly periods at 0.21 times, suggesting increased borrowing to support operations, which may impact liquidity.

In light of these developments, Aarti Pharmalabs has undergone a revision in its score, reflecting the current financial landscape.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News